View
Page
Northland also published a note..."ImmuPharma issued an update on the progress of its Phase 3 clinical trial of LupuzorTM, its lead programme for the potential treatment of Lupus. The company confirmed that the first European sites have now commenced dosing Lupus patients. Recruitment in the study will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe. ImmuPharma’s lead programme is progressing to plan, with patients now being dosed in Europe and America. The Phase 3 clinical trial is expected to deliver a read-out by the end of 2017." pulled from Research Tree
Latest from the Community...
Latest from the Community...
Latest from the Community...
